Physician profile
Robert D Mcelhaney
NPI 1730162124
$6,900.82
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $1,072 · 2021: $1,746 · 2022: $1,173 · 2023: $1,556 · 2024: $69.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610 · Education: $14.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.36 |
| Education | $14.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $984.57 | 2019-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $780.39 | 2019-2024 | Farxiga, Breztri |
| Pfizer INC. | $708.71 | 2019-2023 | |
| Abbvie INC. | $634.90 | 2021-2023 | |
| Lilly USA, LLC | $477.60 | 2019-2023 | Mounjaro, Emgality, Reyvow |
| Sanofi-Aventis U.S. LLC | $423.84 | 2019-2022 | |
| Novo Nordisk INC | $416.24 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $351.59 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $343.66 | 2019-2022 | |
| Astellas Pharma US INC | $260.08 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $227.84 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.00 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $161.02 | 2020-2023 | Eliquis |
| Mylan Specialty L.P. | $131.53 | 2019-2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.95 | 2020-2023 | Xifaxan, Trulance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $89.81 | 2019-2023 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.78 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $74.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $71.24 | 2020-2021 | |
| Lundbeck LLC | $67.84 | 2023 | Rexulti |
| Abbott Laboratories | $66.26 | 2022-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $29.30 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $24.28 | 2023 | Dupixent |
| Amarin Pharma, INC. | $23.28 | 2020 | |
| Supernus Pharmaceuticals, INC. | $22.31 | 2019 | |
| Nevro Corp. | $22.12 | 2021 | |
| Dexcom, INC. | $21.70 | 2021 | |
| Allergan, INC. | $15.69 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.48 | 2020 | |
| Sanofi Pasteur INC. | $15.17 | 2021 | |
| Strongbridge US INC. | $14.95 | 2019 | |
| Eisai INC. | $14.90 | 2020 | |
| Scilex Pharmaceuticals INC. | $14.05 | 2019 | |
| Biodelivery Sciences International, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcelhaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.